Urologic Oncology: Seminars and Original Investigations
Volume 26, Issue 2 , Pages 133-136 , March 2008

Primary chemotherapy with low-dose prolonged infusion gemcitabine and cisplatin in patients with bladder cancer: A Phase II trial

  • Hussein Khaled, M.D.

      Affiliations

    • Department of Medical Oncology, National Cancer Institute, Cairo University, Cairo, Egypt
    • Corresponding Author InformationCorresponding author. Tel.: +00-201-22151040; fax: +368-9711.
    • ,
  • Mohamed E. Emara, M.D.

      Affiliations

    • Department of Medical Oncology, National Cancer Institute, Cairo University, Cairo, Egypt
    • ,
  • Rabab M. Gaafar, M.D.

      Affiliations

    • Department of Medical Oncology, National Cancer Institute, Cairo University, Cairo, Egypt
    • ,
  • Osman Mansour, M.D.

      Affiliations

    • Department of Medical Oncology, National Cancer Institute, Cairo University, Cairo, Egypt
    • ,
  • Ahmed Abdel Warith, M.D.

      Affiliations

    • Department of Medical Oncology, National Cancer Institute, Cairo University, Cairo, Egypt
    • ,
  • Mohamed S. Zaghloul, M.D.

      Affiliations

    • Department of Radiation Oncology, National Cancer Institute, Cairo University, Cairo, Egypt
    • ,
  • Osama El Malt, M.D.

      Affiliations

    • Department of Surgical Oncology, National Cancer Institute, Cairo University, Cairo, Egypt

Received 21 August 2006 ,Revised 8 January 2007 ,Accepted 8 January 2007.

References 

  1. Heinemann V, Schukz L, Issels RD, et al. Gemcitabine: A modulator of intracellular nucleotide and deoxynucleotide metabolism. Semin Oncol. 1995;22(Suppl 11):11–18
  2. Huang P, Plunkett W. Induction of apoptosis by gemcitabine. Semin Oncol. 1995;22(Suppl 11):19–25
  3. Plunkett W, Huang P, Xu YZ, et al. Gemcitabine: Metabolism, mechanisms of action, and self-potentiation. Semin Oncol. 1995;22(Suppl 11):3–10
  4. Abbruzzese JL, Grunewald R, Weeks EA. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol. 1991;9:491–498
  5. Grunewald R, Abbruzzese JL, Tarassoff P, et al. Saturation of 2, 2-difluorodexycytidine 5-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol. 1991;27:258–262
  6. Veerman G, Ruiz van Haperen VW, Vermorken JB. Antitumor activity of prolonged as compared with bolus administration of 2, 2-difluorodexycytidine in vivo against murine colon tumors. Cancer Chemother Pharmacol. 1996;38:335–342
  7. Pollera CF, Ceribelli A, Crecco M. Prolonged infusion of gemcitabine: A clinical phase I study at low-(300 mg/m2) and high-(875 mg/m2) levels. Invest New Drugs. 1997;15:115–121
  8. Akrivakis K, Schmid P, Flath B, et al. Prolonged infusion of gemcitabine in stage IV breast cancer: A phase I study. Anticancer Drugs. 1999;10:525–531
  9. Schmid P, Akrivakis K, Flath B, et al. A phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer. Anticancer Drugs. 1999;10:625–631
  10. Maurel G, Zorrilla M, Puertolas T. Phase I trial of weekly gemcitabine at 3-h infusion in refractory, heavily pretreated advanced solid tumors. Anticancer Drugs. 2001;12:713–717
  11. Schmid P, Schweigert M, Beinert T, et al. Prolonged infusion of gemcitabine in advanced solid tumors: A phase I study. Invest New Drugs. 2005;23:139–146
  12. Parkin DM, Whelan SL, Ferlay J, et al. Cancer incidence in five continents (Vol VIII. IARC Scientific Publication No. 155). Lyon, France: UICC; 2002;
  13. Chester JD, Hall GD, Forester M, et al. Systemic chemotherapy for patients with bladder cancer-current controversies and future directions. Cancer Treat Rev. 2004;30:343–358
  14. Von der Masse H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicancer, phase III study. J Clin Oncol. 2000;18:3068–3077
  15. Ingelfinger JA, Mosreteller FM, Thibodeau LA, et al. Biostatistics in clinical medicine. New York (NY): McGraw-Hill Inc; 1994;
  16. Bajorin DF, Dodd PM, Mazumdar M, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999;17:3173–3181
  17. Khaled HM, Hamza MR, Mansoyr O, et al. A phase II study of gemcitabine plus cisplatin chemotherapy in advanced bilharzial bladder carcinoma. Eur J Cancer. 2000;36(Suppl 2):34–37
  18. Moore MJ, Winquist EW, Murray N. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: A phase II trial if the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1999;17:2876–2881
  19. Kaufman D, Raghavan D, Carducci M. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol. 2000;18:1921–1927
  20. Zwitter M, Kovac V, Smrdel U, et al. Phase I-II trial of low-dose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer. Anticancer Drugs. 2005;16:1129–1134
  21. Schmid P, Krocker J, Jehn C, et al. Primary chemotherapy with gemcitabine as prolonged infusion, non-pegylated liposomal doxorubicin and docetaxel in patients with early breast cancer: Final results of a phase II trial. Ann Oncol. 2005;16:1624–1631

PII: S1078-1439(07)00006-3

doi: 10.1016/j.urolonc.2007.01.013

Urologic Oncology: Seminars and Original Investigations
Volume 26, Issue 2 , Pages 133-136 , March 2008

Article Tools